Tests glibenclamide for nerve pain in people with multiple sclerosis
Tests a long-acting glibenclamide tablet against placebo for nerve pain in multiple sclerosis.
Plain-language title generated from the registry record
Registry title: OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis
Key facts
- Where
- Baltimore, United StatesSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07221799, who can take part
Where in United States
- University of Maryland School of MedicineBaltimore, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Maryland, Baltimore
- Trial code
- NCT07221799
- Record updated
- 28 October 2025
- Original description
This is an early phase safety evaluation of the use of oral extended release (OER) glibenclamide, which is otherwise known as glyburide, for use as a treatment for neurologic pain in people with multiple sclerosis. Patients will receive medication to assess safety and tolerability.Read full original descriptionShow less
A Pilot Study of the Pharmacodynamics and Clinical Effects of Oral Extended Release (OER) Glibenclamide in Multiple Sclerosis Patients With Neuropathic Pain
This is an early phase safety evaluation of the use of oral extended release (OER) glibenclamide, which is otherwise known as glyburide, for use as a treatment for neurologic pain in people with multiple sclerosis. Patients will receive medication to assess safety and tolerability.
Inclusion: Age 18-65; Diagnosis of multiple sclerosis per the 2017 Revised McDonald Criteria; Score of ≥ 19 on the painDETECT questionnaire.
Exclusion: T2DM treated with insulin or oral medication; Breast-feeding women who do not agree to stop breastfeeding during Study Drug infusion and for 7 days following the end of Study Drug infusion; Known allergy to sulfa or specific allergy to sulfonylurea drugs; Severe renal disorder from the patient's history (e.g., dialysis) or eGFR of < 30 ml/min.1.73m2; Severe liver disease, or ALT > 3 times upper limit of normal or bilirubin >2 times normal; Acute ST elevation myocardial infarction, and/or acute decompensated heart failure, and/or QTc > 520 ms, and/or known history of cardiac arrest (PEA, VT, VF, asystole), and/or admission for an acute coronary syndrome, myocardial infarction, or coronary intervention within the past 3 months; Blood glucose < 55 mg/dL at enrollment or immediately prior to administration of study drug or a clinically significant history of hypoglycemia; Pregnancy. Women must be either postmenopausal, permanently sterilized or, if ≤50 years old must have a negative test for pregnancy obtained before enrollment; Known sulfonylurea treatment within 7 days. Sulfonylureas include glyburide/glibenclamide (Diabeta, Glynase); glyburide plus metformin (Glucovance); glimepiride (Amaryl); repaglinide (Prandin); nateglinide (Starlix); glipizide (Glucotrol, GlibeneseR, MinodiabR); gliclazide (DiamicronR); tolbutamide (Orinase, Tolinase); glibornuride (Glutril); Known G6PD enzyme deficiency.